

CITATION REPORT

List of articles citing

Comparison of New Drug Accessibility and Price Between Japan and Major European Countries

DOI: 10.1177/2168479017706716

Therapeutic Innovation and Regulatory Science, 2017,
51, 604-611.

Source: <https://exaly.com/paper-pdf/67199763/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Evidence-Based Valuation in Oncology:: Lessons Learned from a Case Study. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 403-411	1.2	3
4	Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. <i>BMJ Open</i> , 2019 , 9, e022293	3	5
3	Access to medicines - a systematic review of the literature. <i>Research in Social and Administrative Pharmacy</i> , 2020 , 16, 1166-1176	2.9	2
2	Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. <i>Health Policy</i> , 2020 , 124, 231-238	3.2	
1	Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea. <i>Clinical and Translational Science</i> , 2020 , 13, 916-922	4.9	2